ClinicalTrials.gg
CompletedNCT02322866Updated Feb 1, 2019Results posted

Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne

A Phase 3 interventional study of Sarecycline and Placebo in Acne Vulgaris, sponsored by Almirall, S.A.. Completed at 57 sites in United States. Open to participants aged 9 Years to 45 Years. Per ClinicalTrials.gov, last updated 2019-02-01.

Sponsored by Almirall, S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,034
Allocation
Randomized
Ages
9 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 373 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.

Enrollment
25th of 353
1,034 · median 78
Started
2014
with 16 others
Phase 3
76 of 373
1 open now
Registered
159th of 373
by date
Lead sponsor
8 of 373
Almirall, S.A.

Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 25th largest by enrollment of the 353 interventional ones that give a count, is one of 17 that started in 2014, is one of 76 in phase 3, and was the 159th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

20 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of an approximate 1.5 mg/kg/day dose of oral sarecycline compared to placebo in the treatment of moderate to severe facial acne vulgaris

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • acne
04

Who can participate

Ages eligible
9 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed or assent form
  • Male/female, 9 to 45 years of age, inclusive
  • Body weight between 33 and 136 kg, inclusive
  • Facial acne vulgaris with:
  • 20-50 inflammatory lesions (papules, pustules and nodules)
  • 30-100 noninflammatory lesions (open and closed comedones)
  • No more than 2 nodules
  • Investigator's Global Assessment (IGA) score of moderate (3) or severe (4)
  • Negative urine pregnancy test at baseline - females of
  • Agrees to use an effective method of throughout the study
  • Refrain from use of any other acne medications and medicated cleansers, and avoid excessive sun exposure and tanning booths for duration of study
  • Able to fulfill the requirements of protocol, indicated willingness to participate in the study and agrees to all study procedures (including mandatory photography) by providing written informed consent/assent and an authorization to disclose protected health information (PHI).

Exclusion criteria

Exclusion Criteria:

  • Has a dermatological condition of the face that could interfere with the clinical evaluations
  • Has a history of any of the following:
  • Allergy to tetracycline-class antibiotics or to any ingredient in the study drug
  • Pseudomembranous colitis or antibiotic-associated colitis
  • Treated for any type of cancer within the last 6 months
  • Has known resistance to other tetracyclines
  • Has receive any of the following treatments within 12 weeks of screening:
  • Systemic retinoids
  • Systemic
  • Androgens/anti-androgenic therapy (eg, anabolic steroids, spironolactone)
  • Non-medicated procedures for the treatment of acne (eg, laser, light or ThermaClear)
  • Has used any acne affecting treatment without an appropriate
  • Has initiated hormonal use within 12 weeks prior to screening or plans to initiate or switch hormonal contraceptive products during the study period
  • Is pregnant, lactating or planning a pregnancy during the study period
  • Has any other disorder causing hyperandrogenism including, but not limited to polycystic ovary syndrome, adrenal or ovarian tumors, Cushings disease or congenital adrenal hyperplasia
  • Has drug-induced acne
  • Has significant intercurrent illness, psychiatric disposition or other factors that, in the opinion of the Investigator or Medical Monitor, precludes participation in the study
  • Is currently participating, or has participated within 30 days prior to the screening period in an drug or device study
  • Has previously participated in any clinical trial involving the use of sarecycline
  • Is judged by the Investigator to be unsuitable for any reason.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,034 participants (actual)

Study arms

  • Experimental
    Sarecycline

    Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.

    Drug: Sarecycline

  • Placebo comparator
    Placebo

    Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.

    Drug: Placebo

Interventions

  • 1.5 mg/kg/day taken orally at the same time each day.

  • DrugPlacebo

    Placebo-matching sarecycline tablets, taken orally at the same time each day.

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 12

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 centimeter (cm) in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 12

  2. Percentage of Participants With Investigator's Global Assessment (IGA) Scale Success at Week 12

    The investigator assessed the participant's inflammatory lesions on the face using the IGA 5-point scale. The scale ranges from 0 (best): clear, no evidence of papules or pustules to 4 (worst): severe, inflammatory lesions are more apparent, many papules/pustules, there may or may not be a few nodulocytic lesions. Success was defined as at least a 2-point decrease (improvement) from Baseline on the IGA assessment as well as a score of clear (0) or almost clear (1). The percentage of participants who achieved success is reported. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Week 12

Secondary outcomes

  1. Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 12

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Facial inflammatory lesions (pustules, papules, and nodular lesions) were counted and recorded separately. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 12

  2. Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 9

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Facial inflammatory lesions (pustules, papules, and nodular lesions) were counted and recorded separately. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 9

  3. Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 6

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Facial inflammatory lesions (pustules, papules, and nodular lesions) were counted and recorded separately. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 6

  4. Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 3

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Facial inflammatory lesions (pustules, papules, and nodular lesions) were counted and recorded separately. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 3

  5. Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 9

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Facial inflammatory lesions (pustules, papules, and nodular lesions) were counted and recorded separately. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 9

  6. Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 6

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Facial inflammatory lesions (pustules, papules, and nodular lesions) were counted and recorded separately. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 6

  7. Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 3

    Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Facial inflammatory lesions (pustules, papules, and nodular lesions) were counted and recorded separately. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

    Time frame: Baseline (Day 1) to Week 3

07

Results

Posted May 7, 2018

Participant flow

Participant flow — Overall Study
MilestonePlaceboSarecycline
Started515519
Completed444433
Not completed7186
Withdrew: Adverse event611
Withdrew: Withdrawal of consent1625
Withdrew: Lost to follow-up3639
Withdrew: Protocol violation10
Withdrew: Noncompliance with treatment34
Withdrew: Lack of efficacy31
Withdrew: Other miscellaneous reasons66

Outcome measures

PrimaryAbsolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 12

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 centimeter (cm) in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Least squares mean · lesion count
Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 12
lesion countPlaceboSarecycline
Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 12-10.7 ± 0.5-15.1 ± 0.6
Statistical analysis
  • Placebo vs Sarecycline · ANCOVA · p = < 0.0001 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -4.4 · 95% CI -5.8 to -2.9sarecycline - placebo
PrimaryPercentage of Participants With Investigator's Global Assessment (IGA) Scale Success at Week 12

The investigator assessed the participant's inflammatory lesions on the face using the IGA 5-point scale. The scale ranges from 0 (best): clear, no evidence of papules or pustules to 4 (worst): severe, inflammatory lesions are more apparent, many papules/pustules, there may or may not be a few nodulocytic lesions. Success was defined as at least a 2-point decrease (improvement) from Baseline on the IGA assessment as well as a score of clear (0) or almost clear (1). The percentage of participants who achieved success is reported. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Investigator's Global Assessment (IGA) Scale Success at Week 12
percentage of participantsPlaceboSarecycline
Percentage of Participants With Investigator's Global Assessment (IGA) Scale Success at Week 1215.322.6
Statistical analysis
  • Placebo vs Sarecycline · Cochran-Mantel-Haenszel · p = 0.0038 (P-values were based on the test of general association between the response and treatment group using Cochran-Mantel-Haenszel test with pooled site as stratification factor.) · Treatment rate difference: 7.30 · 95% CI 2.53 to 12.07sarecycline - placebo
SecondaryPercent Change From Baseline in Facial Inflammatory Lesion Counts at Week 12

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Facial inflammatory lesions (pustules, papules, and nodular lesions) were counted and recorded separately. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 12
Reported as:
Least squares mean · percent change in lesion counts
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 12
percent change in lesion countsPlaceboSarecycline
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 12-35.4 ± 1.8-49.9 ± 1.9
Statistical analysis
  • Placebo vs Sarecycline · ANCOVA · p = < 0.0001 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -14.4 · 95% CI -19.4 to -9.5sarecycline - placebo
SecondaryPercent Change From Baseline in Facial Inflammatory Lesion Counts at Week 9

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Facial inflammatory lesions (pustules, papules, and nodular lesions) were counted and recorded separately. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 9
Reported as:
Least squares mean · percent change in lesion counts
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 9
percent change in lesion countsPlaceboSarecycline
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 9-31.9 ± 1.7-44.5 ± 1.7
Statistical analysis
  • Placebo vs Sarecycline · ANCOVA · p = < 0.0001 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -12.6 · 95% CI -17.3 to -7.9sarecycline - placebo
SecondaryPercent Change From Baseline in Facial Inflammatory Lesion Counts at Week 6

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Facial inflammatory lesions (pustules, papules, and nodular lesions) were counted and recorded separately. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 6
Reported as:
Least squares mean · percent change in lesion counts
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 6
percent change in lesion countsPlaceboSarecycline
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 6-27.3 ± 1.6-39.1 ± 1.6
Statistical analysis
  • Placebo vs Sarecycline · ANCOVA · p = < 0.0001 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -11.8 · 95% CI -16.1 to -7.5sarecycline - placebo
SecondaryPercent Change From Baseline in Facial Inflammatory Lesion Counts at Week 3

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Facial inflammatory lesions (pustules, papules, and nodular lesions) were counted and recorded separately. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 3
Reported as:
Least squares mean · percent change in lesion counts
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 3
percent change in lesion countsPlaceboSarecycline
Percent Change From Baseline in Facial Inflammatory Lesion Counts at Week 3-18.6 ± 1.6-28.0 ± 1.5
Statistical analysis
  • Placebo vs Sarecycline · ANCOVA · p = < 0.0001 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -9.4 · 95% CI -13.5 to -5.3sarecycline - placebo
SecondaryAbsolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 9

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Facial inflammatory lesions (pustules, papules, and nodular lesions) were counted and recorded separately. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 9
Reported as:
Least squares mean · lesion count
Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 9
lesion countPlaceboSarecycline
Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 9-9.5 ± 0.5-13.4 ± 0.5
Statistical analysis
  • Placebo vs Sarecycline · ANCOVA · p = < 0.0001 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -3.8 · 95% CI -5.2 to -2.5sarecycline - placebo
SecondaryAbsolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 6

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Facial inflammatory lesions (pustules, papules, and nodular lesions) were counted and recorded separately. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 6
Reported as:
Least squares mean · lesion count
Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 6
lesion countPlaceboSarecycline
Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 6-8.0 ± 0.5-11.7 ± 0.5
Statistical analysis
  • Placebo vs Sarecycline · ANCOVA · p = < 0.0001 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -3.7 · 95% CI -5.0 to -2.4sarecycline - placebo
SecondaryAbsolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 3

Facial area lesion counts were made at the forehead, left and right cheeks, nose, and chin at baseline and at each treatment period visit. Facial inflammatory lesions (pustules, papules, and nodular lesions) were counted and recorded separately. Inflammatory lesion counts were based on the following definitions: papule: a solid, elevated lesion \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; pustule: an elevated lesion containing pus \< 0.5 cm in diameter (by inspection) with surrounding erythematous halo; nodule: palpable solid erythematous lesion \> 0.5 cm in diameter (by inspection); has depth, not necessarily elevated. A negative change from Baseline indicates that the number of inflammatory lesions decreased. Analyses were based on analysis of covariance (ANCOVA) model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.

Time frame:
Baseline (Day 1) to Week 3
Reported as:
Least squares mean · lesion count
Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 3
lesion countPlaceboSarecycline
Absolute Change From Baseline in Facial Inflammatory Lesion Counts at Week 3-5.5 ± 0.5-8.4 ± 0.5
Statistical analysis
  • Placebo vs Sarecycline · ANCOVA · p = < 0.0001 (Analyses were based on ANCOVA model for the endpoint with treatment group and pooled study center as factors and baseline value as a covariate.) · Least squares mean difference: -2.9 · 95% CI -4.1 to -1.7sarecycline - placebo

Adverse events

Collected over Up to 157 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/513 (0%)1/513 (0.2%)0/513 (0%)
Sarecycline0/513 (0%)4/513 (0.8%)0/513 (0%)
Most frequent serious events
Most frequent serious events
EventPlaceboSarecycline
Crohn's diseaseGastrointestinal disorders0/5131/513
TonsillitisInfections and infestations0/5131/513
AbortionPregnancy, puerperium and perinatal conditions0/5131/513
DepressionPsychiatric disorders0/5131/513
Oppositional defiant disorderPsychiatric disorders1/5130/513

Baseline characteristics

Intent-to-treat (ITT) Population included all randomized participants.

Age, Customized
Age, Customized(participants)PlaceboSarecyclineTotal
≥9 and <12 years4711
≥12 and <18 years256227483
≥18 years255285540
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSarecyclineTotal
Female292315607
Male223204427
08

Study locations

57 sites
  • Warner Chilcott Research Site (Site #206)
    Mobile, Alabama 36608, United States
  • Warner Chilcott Research Site (Site #236)
    Hot Springs, Arkansas 71913, United States
  • Warner Chilcott Research Site (Site #245)
    Carlsbad, California 92008, United States
  • Warner Chilcott Research Site (Site #234)
    Encinitas, California 92024, United States
  • Warner Chilcott Research Site (Site #209)
    Fremont, California 94538, United States
  • Warner Chilcott Research Site (Site #215)
    Oceanside, California 92056, United States
  • Warner Chilcott Research Site (Site #204)
    San Diego, California 92123, United States
  • Warner Chilcott Research Site (Site #254)
    San Diego, California 92123, United States
  • Warner Chilcott Research Site (Site #257)
    Santa Ana, California 92701, United States
  • Warner Chilcott Research Site (Site #243)
    Santa Monica, California 90404, United States
  • Warner Chilcott Research Site (Site #222)
    Denver, Colorado 80220, United States
  • Warner Chilcott Research Site (Site #237)
    Aventura, Florida 33180, United States
  • Warner Chilcott Research Site (Site #226)
    Clearwater, Florida 33761, United States
  • Warner Chilcott Research Site (Site #238)
    Jupiter, Florida 33458, United States
  • Warner Chilcott Research Site (Site #255)
    Lauderdale Lakes, Florida 33319, United States
  • Warner Chilcott Research Site (Site #249)
    Miami, Florida 33142, United States
  • Warner Chilcott Research Site (Site #202)
    Miami, Florida 33144, United States
  • Warner Chilcott Research Site (Site #211)
    Miramar, Florida 33027, United States
  • Warner Chilcott Research Site (Site #247)
    Ocala, Florida 34471, United States
  • Warner Chilcott Research Site (Site #241)
    Orlando, Florida 32806, United States
  • Warner Chilcott Research Site (Site #228)
    Pinellas Park, Florida 33781, United States
  • Warner Chilcott Research Site (Site #203)
    Tampa, Florida 33609, United States
  • Warner Chilcott Research Site (Site #242)
    Snellville, Georgia 30078, United States
  • Warner Chilcott Research Site (Site #210)
    Champaign, Illinois 61820, United States
  • Warner Chilcott Research Site (Site #213)
    Louisville, Kentucky 40202, United States
  • Warner Chilcott Research Site (Site #217)
    Rockville, Maryland 20850, United States
  • Warner Chilcott Research Site (Site #248)
    Watertown, Massachusetts 02472, United States
  • Warner Chilcott Research Site (Site #205)
    Bay City, Michigan 48706, United States
  • Warner Chilcott Research Site (Site #251)
    Clarkston, Michigan 48346, United States
  • Warner Chilcott Research Site (Site #235)
    Clinton Township, Michigan 48038, United States
  • Warner Chilcott Research Site (Site #227)
    Fort Gratiot, Michigan 48059, United States
  • Warner Chilcott Research Site (Site #221)
    Fridley, Minnesota 55432, United States
  • Warner Chilcott Research Site (Site #231)
    Omaha, Nebraska 68144, United States
  • Warner Chilcott Research Site (Site #253)
    Newington, New Hampshire 03801, United States
  • Warner Chilcott Research Site (Site #239)
    Albuquerque, New Mexico 87106, United States
  • Warner Chilcott Research Site (Site #208)
    New York, New York 10155, United States
  • Warner Chilcott Research Site (Site #240)
    Rochester, New York 14623, United States
  • Warner Chilcott Research Site (Site #230)
    Stony Brook, New York 11790, United States
  • Warner Chilcott Research Site (Site #229)
    Raleigh, North Carolina 27612, United States
  • Warner Chilcott Research Site (Site #250)
    Wilmington, North Carolina 28405, United States
  • Warner Chilcott Research Site (Site #218)
    Beachwood, Ohio 44122, United States
  • Warner Chilcott Research Site (Site #256)
    Philadelphia, Pennsylvania 19103, United States
  • Warner Chilcott Research Site (Site #214)
    Warwick, Rhode Island 02886, United States
  • Warner Chilcott Research Site (Site #219)
    Fountain Inn, South Carolina 29644, United States
  • Warner Chilcott Research Site (Site #225)
    Goodlettsville, Tennessee 37072, United States
  • Warner Chilcott Research Site (Site #216)
    Knoxville, Tennessee 37922, United States
  • Warner Chilcott Research Site (Site #252)
    Arlington, Texas 76011, United States
  • Warner Chilcott Research Site (Site #220)
    College Station, Texas 77845, United States
  • Warner Chilcott Research Site (Site #201)
    Katy, Texas 77494, United States
  • Warner Chilcott Research Site (Site #223)
    Pflugerville, Texas 78660, United States
  • Warner Chilcott Research Site (Site #207)
    San Antonio, Texas 78218, United States
  • Warner Chilcott Research Site (Site #224)
    Webster, Texas 77598, United States
  • Warner Chilcott Research Site (Site #212)
    West Jordan, Utah 84088, United States
  • Warner Chilcott Research Site (Site #244)
    Norfolk, Virginia 23507, United States
  • Warner Chilcott Research Site (Site #246)
    Seattle, Washington 98105, United States
  • Warner Chilcott Research Site (Site #233)
    Walla Walla, Washington 99362, United States
  • Warner Chilcott Research Site (Site #232)
    Madison, Wisconsin 53719, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Jan 2017, 25 months.

Results were first posted in May 2018, 1 year 3 months after primary completion.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 25 months is above that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2014
First posted
Dec 23, 2014
StartActual
Dec 3, 2014
Primary completionActual
Jan 12, 2017
CompletionActual
Jan 12, 2017
Results first posted
May 7, 2018
Last update
Feb 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02322866
Lead sponsor
Almirall, S.A.
Collaborators
Allergan
Responsible party
Sponsor
First posted
Dec 23, 2014
Start date
Dec 3, 2014
Primary completion
Jan 12, 2017
Completion
Jan 12, 2017
Results posted
May 7, 2018
Last update
Feb 1, 2019

Study contacts

David Berk, MD
study director · Allergan, plc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarecycline

Start the discussion